Efficacy and Safety of Teprotumumab in the Treatment of Thyroid Eye Disease Patients with Long Duration and Low Disease Activity

Published: 17 November 2023| Version 1 | DOI: 10.17632/x38yzs6cd3.1
Contributor:
Raymond Douglas

Description

SUPPLEMENT Efficacy and Safety of Teprotumumab in the Treatment of Thyroid Eye Disease Patients with Long Duration and Low Disease Activity: A Randomised Double-Masked, Placebo-controlled, Multicenter Trial Raymond S. Douglas et al

Files

Categories

Controlled Clinical Trial

Licence